Skip to main content
. Author manuscript; available in PMC: 2017 Sep 30.
Published in final edited form as: Biochem Biophys Res Commun. 2016 Aug 31;478(4):1617–1623. doi: 10.1016/j.bbrc.2016.08.169

Fig. 2.

Fig. 2

Triple-negative breast cancer cell lines express hGBP-1. A. Cells were lysed, proteins separated by SDS-PAGE, and analyzed for the expression of hGBP-1, TUBB3, and actin. B. TMX2-28 cells were transfected with two different shRNAs against eGFP (#1 and #2) and three different shRNAs against hGBP-1 (hGBP-1 #1, #2, and #3). Cells were selected in puromycin and analyzed for hGBP-1 expression by Western blot. All three shRNAs against hGBP-1 knocked down hGBP-1 expression but cells containing shRNAs # 1 and 2 were used in the next assays. C. TMX2-28 cells stably expressing the shRNAs were analyzed for paclitaxel sensitivity by SRB assay. D. Colony assays showed that the cells were very sensitive to the drug; the loss of hGBP-1 did not increase sensitivity.